02:05 PM EST, 11/03/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month target by $25 to $418, reflecting a P/E multiple of 28.0x our 2026 EPS estimate, a premium to SYK's three-year average forward P/E of 27.3x due to strengthening EPS growth and justified by the anticipated strong growth in procedure volumes. We lift our 2025 EPS view by $0.18 to $13.55 and 2026's by $0.08 to $14.94, as we initiate 2027's at $16.71. We see upside potential for shares of SYK following strong Q3 2025 results that demonstrated continued momentum across the company's diversified portfolio. The company delivered solid performance, with net sales of $6.1B (+10.3% Y/Y) and adjusted EPS of $3.19 (+11.1% Y/Y), led by robust organic growth of 9.5%, with strong volume momentum of 9.1%. Management raised full-year 2025 organic growth guidance to 9.8%-10.2% and adjusted EPS guidance to $13.50-$13.60 on sustained product demand and margin expansion efforts. We expect Stryker's sales to grow approximately 10.9% Y/Y in 2025 and 8.5% in 2026.